Data and Safety Monitoring Board (DSMB) for Ocugen’s Phase 1/2 ArMaDa clinical approves medium dose of OCU410
by: Sydney M Crago The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.…